|
 The Food and Drug Administration approved the gene therapy, to be
sold under the name Yescarta, to treat adults with large B-cell
lymphoma, a type of non-Hodgkin lymphoma, who have failed to respond
to other treatments.
Gilead, which recently acquired Kite Pharma, said the list price for
Yescarta, which is to be administered just once to each patient,
would be $373,000.
The price is well below that of the first drug in this new class -
Novartis AG's $475,000 Kymriah. The Novartis gene therapy was
approved in August for B-cell acute lymphoblastic leukemia, the most
common form of childhood cancer in the United States.
Both are chimeric antigen receptor T-cell therapies, or CAR-Ts,
which reprogram the body's own immune cells to recognize and attack
malignant cells.
The high price of CAR-Ts is igniting a new debate over the rising
cost of prescription drugs. Novartis said it would charge for
Kymriah only if patients responded within a month of the treatment,
but Gilead is not following suit.
"We are in ongoing and active discussions with payers, and we have
communicated our openness to considering different solutions that
improve patient access," Gilead spokeswoman Amy Flood said in an
email.
She said the price was set following extensive research with both
government agencies that reimburse for drug costs and private
insurers, and cancer centers.
Gilead Sciences shares rose almost 4 percent to $83 in
after-the-bell trading.
Jefferies analyst Michael Yee said Yescarta could generate sales of
up to $250 million in 2018.
Gilead said about 7,500 lymphoma patients each year in the United
States would be eligible for CAR-T therapy.
The American Cancer Society estimates that 72,240 people will be
diagnosed with non-Hodgkins lymphoma this year and 20,140 people
will die from it. This type of lymphoma accounts for about 4 percent
of all cancers in the United States.
[to top of second column] |
Potentially curative CAR-T therapies are poised to revolutionize
blood cancer treatment, offering therapies tailored to the
individual patient.
The treatments are made from a patient's own infection-fighting
cells. They are extracted, genetically engineered to recognize
cancer cells, and infused back into the patient, where they form an
army to attack and destroy malignant cells, potentially for years.
"Gene therapy has gone from being a promising concept to a practical
solution to deadly and largely untreatable forms of cancer," FDA
Commissioner Scott Gottlieb said in a statement.
In a pivotal clinical trial of more than 100 adults, 51 percent of
patients treated with Yescarta achieved complete remission, far
higher than what is typical with current standard-of-care
treatments.
Gilead agreed in August to pay about $12 billion to acquire Kite
Pharma, two days before the U.S. approval of Novartis' Kymriah
boosted confidence in the entire CAR-T class.
Similar CAR-T treatments are being developed by Juno Therapeutics
Inc, bluebird bio Inc and others.
(Additional reporting by Deena Beasley in Los Angeles; Editing by
Diane Craft and Leslie Adler)
[© 2017 Thomson Reuters. All rights
reserved.] Copyright 2017 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
 |
